US · LLY · DRUG MANUFACTURERS - GENERAL
Eli Lilly and Company (LLY) intrinsic value and stock valuation
$1,347.11as of 2026-11-21 · Mkt cap 1.1T
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Eli Lilly and Company DCF and intrinsic value
InvestorsCraft values LLY with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from LLY’s statements →
Eli Lilly and Company Graham Number
Graham Number: $123.61d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Johnson & Johnson (JNJ) $270.47
- AbbVie Inc. (ABBV) $286.20
- Merck & Co., Inc. (MRK) $133.72
- Novartis AG (NVS) $150.47
- AstraZeneca PLC (AZN) $174.35
- Amgen Inc. (AMGN) $435.64
- Novo Nordisk A/S (NVO) $37.82
- Gilead Sciences, Inc. (GILD) $166.43
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.2B | $45B | $34.1B | $28.5B | $28.3B |
| Operating income | $29.7B | $17.5B | $10.8B | $8.65B | $7.93B |
| Net income | $20.6B | $10.6B | $5.24B | $6.24B | $5.58B |
| EPSd | $23M | $11.7M | $5.8M | $6.57M | $5.85M |
| Operating cash flow | $16.8B | $8.82B | $4.24B | $7.59B | $7.37B |
| Capital expenditure | -$-7.84B | -$-8.4B | -$-7.39B | -$-2.99B | -$-1.98B |
| Free cash flow | $8.97B | $414.3M | -$-3.15B | $4.6B | $5.39B |
| Total assets | $112.5B | $78.7B | $64B | $49.5B | $48.8B |
| Total debt | $42.5B | $33.6B | $25.2B | $16.2B | $16.9B |
| Net debt | $35.3B | $30.4B | $22.4B | $14.2B | $13.1B |
| Total equity | $26.5B | $14.3B | $10.9B | $10.8B | $9.15B |
| Cash and short-term investments | $7.27B | $3.42B | $2.93B | $2.21B | $3.91B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.2B | $45B | $34.1B | $28.5B | $28.3B |
| Cost of revenue | $10.6B | $8.42B | $7.08B | $6.63B | $7.31B |
| Gross profit | $54.6B | $36.6B | $27B | $21.9B | $21B |
| Research and development expenses | $13.3B | $11B | $9.31B | $7.19B | $6.93B |
| Selling, general and administrative expenses | $11.1B | $8.13B | $6.94B | $6.07B | $6.14B |
| Other expenses | $487.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $24.9B | $19.1B | $16.3B | $13.3B | $13.1B |
| Cost and expenses | $35.5B | $27.5B | $23.3B | $19.9B | $20.4B |
| Interest income | $153.3M | $175.2M | $173.6M | $62.8M | $25.4M |
| Interest expense | $795.3M | $780.6M | $485.9M | $331.6M | $339.8M |
| Depreciation and amortization | $1.56B | $1.77B | $1.53B | $1.52B | $1.55B |
| Ebitda | $27.9B | $15.2B | $8.57B | $8.66B | $8.04B |
| Operating income | $29.7B | $17.5B | $10.8B | $8.65B | $7.93B |
| Total other income/expenses, net | -$-3.97B | -$-4.82B | -$-4.23B | -$-1.85B | -$-1.78B |
| Income before tax | $25.7B | $12.7B | $6.55B | $6.81B | $6.16B |
| Income tax expense | $5.09B | $2.09B | $1.31B | $561.6M | $573.8M |
| Net income | $20.6B | $10.6B | $5.24B | $6.24B | $5.58B |
| Weighted average shares outstanding | $898M | $900.6M | $899.4M | $950.2M | $953.7M |
| Weighted average diluted shares outstanding | $898M | $904.1M | $903.3M | $950.2M | $953.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.27B | $3.42B | $2.93B | $2.21B | $3.91B |
| Net receivables | $20.2B | $13.3B | $11.3B | $8.56B | $8.13B |
| Inventory | $13.7B | $7.59B | $5.77B | $4.31B | $3.89B |
| Total current assets | $55.6B | $32.7B | $25.7B | $18B | $18.5B |
| Property, plant and equipment, net | $24.7B | $17.1B | $12.9B | $10.1B | $8.99B |
| Goodwill and intangible assets | $12.4B | $11.9B | $11.8B | $11.3B | $11.6B |
| Long-term investments | $2.8B | $3.22B | $3.05B | $2.9B | $3.21B |
| Total non-current assets | $56.8B | $46B | $38.3B | $31.5B | $30.4B |
| Total assets | $112.5B | $78.7B | $64B | $49.5B | $48.8B |
| Accounts payable | $5.38B | $3.23B | $2.6B | $1.93B | $1.67B |
| Short-term debt | $1.64B | $5.12B | $6.9B | $1.5B | $1.54B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $35.2B | $28.4B | $27.3B | $17.1B | $15.1B |
| Long-term debt | $40.9B | $28.5B | $18.3B | $14.7B | $15.3B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $50.7B | $36.1B | $25.8B | $21.6B | $24.6B |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $85.9B | $64.4B | $53.1B | $38.7B | $39.7B |
| Common stock | $590M | $592.4M | $593.6M | $594.1M | $596.3M |
| Retained earnings | $24.5B | $13.5B | $10.3B | $10B | $8.96B |
| Accumulated other comprehensive income (loss) | -$-2.88B | -$-4.32B | -$-4.33B | -$-3.84B | -$-4.34B |
| Total equity | $26.5B | $14.3B | $10.9B | $10.8B | $9.15B |
| Total investments | $2.91B | $3.37B | $3.16B | $3.05B | $3.3B |
| Total debt | $42.5B | $33.6B | $25.2B | $16.2B | $16.9B |
| Net debt | $35.3B | $30.4B | $22.4B | $14.2B | $13.1B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $20.6B | $10.6B | $5.24B | $6.24B | $5.58B |
| Depreciation and amortization | $2B | $1.77B | $1.53B | $1.52B | $1.55B |
| Stock-based compensation | $626M | $645.6M | $628.5M | $371.1M | $342.8M |
| Change in working capital | -$-8.09B | -$-5.39B | -$-3.06B | -$-800K | -$-1.01B |
| Accounts receivable | -$-7B | -$-2.16B | -$-2.45B | -$-299.6M | -$-1.28B |
| Inventory | -$-4.67B | -$-2.51B | -$-1.43B | -$-599.7M | -$-235.9M |
| Accounts payable | $10.2B | $2.61B | $4.27B | $1.33B | -$-1.01B |
| Net cash provided by operating activities | $16.8B | $8.82B | $4.24B | $7.59B | $7.37B |
| Investments in property, plant and equipment | -$-7.84B | -$-5.06B | -$-3.45B | -$-1.85B | -$-1.31B |
| Acquisitions, net | -$-661M | -$-947.7M | -$-1.04B | -$-327.2M | -$-747.4M |
| Net cash used for investing activities | -$-10.97B | -$-9.3B | -$-7.15B | -$-3.76B | -$-2.87B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-4.11B | -$-2.5B | -$-750M | -$-1.5B | -$-1.25B |
| Dividends paid | -$-5.38B | -$-4.68B | -$-4.07B | -$-3.54B | -$-3.09B |
| Net cash used for financing activities | -$-2.21B | $1.23B | $3.5B | -$-5.41B | -$-4.13B |
| Net change in cash | $4B | $449.8M | $751.6M | -$-1.75B | $161.4M |
| Cash at end of period | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Operating cash flow | $16.8B | $8.82B | $4.24B | $7.59B | $7.37B |
| Capital expenditure | -$-7.84B | -$-8.4B | -$-7.39B | -$-2.99B | -$-1.98B |
| Free cash flow | $8.97B | $414.3M | -$-3.15B | $4.6B | $5.39B |
Line items
Line items
Line items
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- CEO
- David A. Ricks
- Employees
- 50K
- Beta
- 0.51
Included in
Explore
Frequently asked questions
What is the intrinsic value of Eli Lilly and Company (LLY)?
Eli Lilly and Company (LLY) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LLY undervalued?
LLY trades at a price of $1,347.11 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.